The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.

Erin T. Jenkins, Donald M. Jensen

Research output: Contribution to journalReview article


An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.

Original languageEnglish
Pages (from-to)879-891
Number of pages13
JournalInfectious Disease Clinics of North America
Issue number4
StatePublished - Dec 2012
Externally publishedYes


All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this